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BISAP SCORING SYSTEM FOR PREDICTINGTHE SEVERITY AND PROGNOSIS OF 
ACUTE PANCREATITIS 
Abstract 
Background: Early accurate severity assessment of patients with acute pancreatitis (AP) is cruicial to 
decide on the acute management and predict outcomes and prognosis.This is done through multiple 
scoring systems of which serum procalcitonin (PCT) and BISAP has shown promising results. 
However,data comparing these methods is still conflicting. Objectives: we aim to assess the role of 
PCT as a sole indicator and compare it to BISAP in determining severity and prognosis of AP. Methods: 
Retrospective chart review of all AP cases between June 2012 and February 2017 at Makassed General 
Hospital, with at least one reading of PCT documented in records. Data regarding patients’ demographics 
and outcomes were collected. Procalcitonin levels and trends were compared to severity classes and 
BISAP scores regarding various outcomes of AP. Results: Forty-four patients met our inclusion criteria. 
Based on the revised Atlanta classification, 26 patients had mild, four moderate and 14 severe AP. Mean 
serum PCT levels were found to correlate with severity classes (1.28 with mild versus 4.81 with moderate-
severe AP; P < 0 .0001). This was even more prominent on follow-up testing after 48hours (1.67 vs 12.89 
respectively; P=0.01). This proportional relation was again noted with BISAP scores of 0,1 and 2 where the 
mean PCT was 0.1,5.0 and 19.1 respectively. A trend of decrease in serial PCT was also noted with mild as 
compared to a trend of rising PCT in moderate-severe AP. Conclusion: Initial and serial PCT levels directly 
correlated with disease severity and might offer significant additional prognostic value in AP. 
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Prognosis; Severity; Serum procalcitonin; Acute pancreatitis 
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ABSTRACT: Background: Early accurate severity assessment of patients with acute 
pancreatitis (AP) is cruicial to decide on the acute management and predict outcomes and 
prognosis.This is done through multiple scoring systems of which serum procalcitonin (PCT) 
and BISAP has shown promising results. However,data comparing these methods is still 
conflicting. Objectives: we aim to assess the role of PCT as a sole indicator and compare it 
to BISAP in determining severity and prognosis of AP. Methods: Retrospective chart review 
of all AP cases between June2012 and February2017 at Makassed General Hospital, with at 
least one reading of PCT documented in records. Data regarding patients’ demographics 
and outcomes were collected. Procalcitonin levels and trends were compared to severity 
classes and BISAP scores regarding various outcomes of AP. Results: Forty-four patients 
met our inclusion criteria. Based on the revised Atlanta classification, 26 patients had mild, 
four moderate and 14 severe AP. Mean serum PCT levels were found to correlate with 
severity classes (1.28 with mild versus 4.81 with moderate-severe AP; P<0.0001). This was 
even more prominent on follow-up testing after 48hours (1.67 vs 12.89 respectively;P=0.01). 
This proportional relation was again noted with BISAP scores of 0,1 and 2 where the mean 
PCT was 0.1,5.0 and 19.1 respectively. A trend of decrease in serial PCT was also noted with 
mild as compared to a trend of rising PCT in moderate-severe AP. 
Conclusion: Initial and serial PCT levels directly correlated with disease severity and might 
offer significant additional prognostic value in AP. 
KEYWORDS: Prognosis; Severity; Serum procalcitonin; Acute pancreatitis 
1. INTRODUCTION
Acute pancreatitis (AP) is an inflammatory condition of the pancreas characterized by severe 
Characteristic epigastria pain along with an elevation of pancreatic enzymes, namely amylase and lipase 
(Kusske,1996) .Approximately 20 percent of cases develop moderately severe or severe acute pancreatitis, 
characterized by local complications or organ failure. Expectedly, patients with severe or necrotizing 
pancreatitis had a significantly higher mortality when compared to patients with mild interstitial pancreatitis 
(17 versus 3 percent) (Banks, 2006). Tremendous research efforts were put into assessing the severity and 
prognostic factors of AP in order to help in the management as well as to determine the best in-hospital setting 
for such patients. The revised Atlanta classification system stratifies patients to mild, moderate and severe 
based on the presence or absence of local or systemic complications and of organ failure (Lee, 2016).Different 
predictive models and scoring systems were developed and validated over the past few decades to aid in 
prognostication, including the APACHE II and the Ranson’s criteria were among the early scoring systems 
that showed good accuracy inpredicting the severity of pancreatitis; however, they were limited by their 
complicated multiple parameters and the time delay needed to fulfill its criteria (Yang, 2014). More recently, 
the bedside index of severity in acute pancreatitis (BISAP) –a more simple and practical score- was tested and 
validated for this purpose and showed similar sensitivity and predictive value when compared to the other 
previous scores (Papachristou, 2010).
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Aiming at finding better and simpler prognostic indicator, small studies addressed the utility of serum 
procalcitonin (PCT)levels in determining outcomes of patients with AP. PCT is the inactive pro-peptide of the 
hormone calcitonin, which is involved in calcium homeostasis. The increased serum PCT correlates closely 
with the inflammatory response of a host to microbial infections, namely bacterial and fungal infections 
(Villatoro, 2010). In patients who suffer from acute pancreatitis, PCT has been shown to predict the 
development of infected pancreatic necrosis (Al-Nawas, 1996) . In addition, it was suggested that PCT might 
be an early predictor of severity and organ failure in patients with AP (Modrau, 2005). The significance of 
measuring the PCT level in the assessment of the severity of acute pancreatitis as well as predicting the risk of 
developing infected pancreatic necrosis was tested inseveral studies. Systematic reviews of these studies 
yielded contradicting results. The most recent one published in 2009 suggested a valuable role of serum PCT 
in predicting the severity of acute pancreatitis and the risk of developing infected pancreatic necrosis (Mofidi, 
2009). The sensitivity and specificity of PCT for predicting the development of severe AP were 0.72 and 0.86, 
respectively. Moreover, the sensitivity and specificity of PCT for prediction of infected pancreatic necrosis 
were 0.80 and 0.91 (95% CI = 13.8--58.3) (Al-Nawas, 1996) .When comparing PCT to BISAP score, data were 
also contradicting. A Korean study in 2013 compared BISAP to other scoring systems including PCT, showed 
that BISAP was more accurate than PCT (BISAP 84% accurate and PCT 76%) (Kim, 2013). However, data is 
still insufficient. 
In this study, we aim to assess the role of procalcitonin and to compare it to BISAP in determining the 
disease severity and prognosis according to revised Atlanta Classification for severity of acute pancreatitis 
2. MATERIALS AND METHODS
2.1 Setting and Data Collection
This is a retrospective chart review of all patients diagnosed with acute pancreatitis who were 
admitted to Makassed General Hospital (MGH) between June 2012 (the date were PCT was first 
introduced to our laboratory) and February 2017. Data were retrieved from the patients’ electronic 
medical records. Only patients above the age of 18 at diagnosis, with at least one reading of Procalcitonin 
in their charts and with clear documentation sufficient for the calculation of BISAP score were selected 
for data collection and comparison. Exclusion criteria included patients with chronic pancreatitis, 
preceding active sepsis from a definitive focus other than AP and those with incomplete chart 
documentation. Datathat were collected from the selected charts included: Patients’ demographics, 
associated comorbidities, etiology of AP, results of any imaging performed, the presence of any local 
complications or the occurrence of any organ failure (needed for the revised atlanta criteria), the criteria 
for calculating the BISAP score, PCT readings, duration of hospital stay, the use of antibiotics, the need 
for intervention, and mortality. PCT levels were measured using an immunoturbidimetry method (Roche 
Diagnostics, Indianapolis, Ind) and an enzyme-linked fluorescent assay (bioMerieux, France), 
respectively. 
Patients were first categorized into mild, moderate and severe AP based on the criteria for the revised 
Atlanta classification. The BISAP score and the initial as well as the other PCT readings were then plotted 
and comparison was performed to show the concordance between these three predictive modelswith 
respect to the various outcomes of AP. 
Definitions 
Revised Atlanta classification system: divides patients  with  AP into  a. mild  AP, characterized 
by the absence of any organ failure and local or systemic complications. (ii) Moderately severe AP, 
characterized by transient organ failure (resolving within 48 hours) and/or local or systemic 
complications without persistent organ failure. (iii) Severe acute pancreatitis, characterized by persistent 
organ failure that may involve one or multiple organs 
BISAP “Bedside Index for Severity in Acute Pancreatitis”: is a score that has been developed to 
identify patients at high risk for mortality or severe disease early during the course of acute pancreatitis. 
It gives one point to each of the following five criteria: Serum BUN of more than 25mg/dl, Impaired 
mental status, presence of systemic immune response syndrome (SIRS), age > 60 years, and the 
presence of pleural effusion. 
Procalcitonin: A biochemical marker (a peptide precursor of hormone calcitonin) composed of 
116amino acids and produced by cells of thyroid, lungs, and intestines. Its level rise in bacterial 
infections, not in viral or non-infectious inflammations. It is used as a marker for  sepsis  with 
sensitivity (85%) and specificity (91%) for differentiating patients with systemic inflammatory response 
syndrome (SIRS) from those with sepsis (Gurda-Duda, 20 
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2.2 Statistical analysis 
The Statistical Package for Social Sciences (SPSS, version 21) program was used for data entry, 
management, and analyses. A p-value of <0.05 is used to indicate statistical significance.Categorical 
variables are presented as number and percent, whereas continuous variables are presented as mean and 
standard deviation. Bivariate analysis was carried out by using the chi square for comparing categorical 
variables, whereas continuous ones were compared using the Student's t-test. 
3. RESULTS:
The total number of patients who met the study’s inclusion criteria was 44 patients. Twenty-six patients 
(59%) were found to have mild APaccording to the revised Atlanta classification, whereas 4 patients (9%) had 
moderately severe AP and 14 patients (32%) had severe AP. Because of the small number of patients with 
moderate AP, and because this category shares some similar characteristics with patients having severe AP, 
these two groups were combined together under “moderate-severe AP” category, and were compared to 
patients with “mild AP”.
The two groups were similar with respect to baseline characteristics including age and gender (Table 1). 
Table 1: Characteristics of 44 Patients with Acute Pancreatitis 
The most common etiology for AP was biliary(40.9%). Other causes included alcohol (6.6%), and 
hypertriglyceridemia (14.1%), drug induced (9%) and post ERCP pancreatitis (4.5%). Expectedly, patients 
with moderate-severe AP had worse outcomes with 13 cases requiring ICU admissions (72.2%) of which 9 
needed mechanical ventilation (50%) and a total of 6 in-hospital mortalities (33.3%) as compared to none in 
the mild AP group. Both groups had similar surgical intervention (mainly cholecystectomy) and antibiotics use 
rates. 
Moreover, the hospitalization duration was significantly higher (mean =17.11 ±9.40) among 
moderate-severe pancreatitis patients. 
Both BISAP score and PCT levels were significantly higher in moderate-severe acute pancreatitis patients 
when compared to those of mild disease (p<0.0001) (Table2). 
Pancreatitis 
Mild 
N=26 
Moderate-Severe 
N=18 P-value
Age, mean (±SD) 59.50 (±20.67) 61.28 (±20.97) 0.77 
Gender 
Male 
Female 
15 (57.7%) 
11 (42.3%) 
6 (33.3%) 
12 (66.7%) 
0.14 
Etiology 
Alcoholic 2 (7.7%) 1 (5.6%) 1.00 
Biliary 11 (42.3%) 7 (38.9%) 0.75 
Hypertriglyceridemia 3 (11.5%) 3 (16.7%) 0.68 
Hypercalcemia 0 (0.0%) 0 (0.0%) NA 
Drug induced 3 1 (5.6%) NS 
Post-ERCP 1 (5.6%) 1 (5.6%) 
Other 11 (42.3%) 7 (38.9%) 1.00 
Outcome 
ICU admission 0 (0.0%) 13 (72.2%) <0.0001 
Mechanical ventilation 0 (0.0%) 9 (50.0%) <0.0001 
Necrosis 0 (0.0%) 1 (5.6%) 0.41 
Antibiotic use 20 (76.9%) 18 (100.0%) 0.07 
Intervention 8 (30.8%) 3 (16.7%) 0.48 
Mortality 0 (0.0%) 6 (33.3%) 0.003 
Duration of hospitalization, mean (±SD) 6.69 (±3.80) 17.11 (±9.40) <0.0001 
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Table 2: Correlation between revised Atlanta classification and the mean BISAP score and mean PCT levels. 
Interestingly, there was a clear and linear quantitative correlation between the mean PCT level upon 
admission and after 48 hours with the severity of AP and with the BISAP score. Even when we subdivided the 
patients into mild , moderate and severe categories, the mean PCT level seemed to proportionally rise with the 
increase in the severity, from 1.27 in patients with mild, to 2.20 in moderate and 5.56 in severe AP. Fifty 
percent of patients with moderate-severe AP had a PCT level above the cutoff of 2 as compared to only 7% in 
patients with mild AP. Moreover, there was a greater tendency of having a rising PCT level by more than 50% 
after 48 hours in severe cases (30%) as compared to mild cases (8%). Similarly, 75% of patients with mild AP 
showed a drop of PCT within the first 48 hours as compared to 50% of patients with moderate and severe cases 
(Appendix1). 
When subdividing the patients into the 5 possible BISAP score, PCT levels were correlating with severity 
from 0 to 2 and to a lesser extent at BISAP 3, however this relation was lost at higher BISAP scores, probably 
due to the small number of patients (table 3). 
Table 3: Correlation between different BISAP scores and Procalcitonin Levels in Acute Pancreatitis. 
Pro-calcitonin p-value
BISAP score (n) 
0.010 
0 (n=10) 
1 (n=10) 
2 (n=10) 
3 (n=6) 
4 (n=7) 
5 (n=1) 
0.11 (±0.63) 
5.00 (±0.63) 
19.08 (±33.36) 
8.12 (±14.48) 
2.05 (±1.72) 
15.54 (NA) 
Pancreatitis 
Mild 
N=26 
Moderate- 
Severe 
N=18 
P- 
value 
Scoring/biochemical markers 
BISAP score, mean (±SD) 1.12 (±1.18) 2.89 (±1.18) <0.00 01 
Procalcitonin (PCT1), mean (±SD) 1.28 (±3.73) 4.81 (±6.05) <0.00 01 
Procalcitonin (PCT2), mean (±SD) 1.67 (±4.61) 12.89 (±26.28) 0. 01 
Procalcitonin (PCT1+PCT2), mean (±SD) 2.05 (±6.71) 14.84 (±25.92) <0.00 01 
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There was no correlation between the duration of hospitalization with respect to PCT levels (Figure1). 
Fig. 1 Relationship between the duration of hospitalization and PCT levels 
Of notice, there is a wide distribution for PCT in BISAP score 2 as compared to BISAP score of 3 and 4 
( Figure 2). 
Fig. 2 Relationship between Procalcitonin Levels and BISAP score 
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4. DISCUSSION:
AP is a serious medical condition that places a considerable burden on the healthcare system. It is of utmost 
importance to adequately categorize patients into the various severity classes and to accurately determine the 
patients with the worse prognosis in order to manage these cases aggressively and thus reduce the high 
mortality rates of such condition. Unfortunately, the scoring systems used at present are often inadequate in 
patients with severe AP, which is characterized by rapidly progressive multiple system organ dysfunction. 
Therefore, a simple scoring systems or single specific biomarkers that can predict the prognosis of AP are 
needed.
Procalcitonin, an early marker of systemic bacterial infection, sepsis, and multiorgan failure, was 
introduced as a prognostic marker of AP in the recent years, focusing on systemic inflammation and organ 
failure in the early stage of AP (Modrau, 2005). Review of literature about its efficacy revealed some debate 
about the role of this biochemical marker as a prognostic factor.One study in 2008 by Gurda-Duda et al.(Gurda- 
Duda, 2008), stated that the early prediction of severe AP was achievable by measuring PCT on admission and 
following it up within
48 hours. Subsequent studies have compared the value of serum Procalcitonin to other prognostic markers 
such as CRP and Interleukin-6(IL-6) where it showed a higher significance. However, results were variable in 
relation to Procalcitonin due to small study sample size and multi-center studies. A Korean study in 2012 by 
Kim et al compared the clinical significance between BISAP and PCT. It stated that a BISAP score (≥ 2) was 
more accurate (84%) at predicting severity of AP and superior to serum PCT (≥ 3.29 ng/mL, 76% Accuracy) 
[10].
In our study, we aimed to study the value of serum Procalcitonin in severity assessment of AP and to 
compare it to BISAP. The relation between the absolute quantitative levels of PCT and the severity class was 
clear and proportional, denoting a significant additional role that can help in the prognostication of patients 
presenting with AP. Although the correlation of the PCT level was less evident with higher BISAP scores, 
which is mostly attributed to the very small number of patients having a score of 5 (only 1 patient), the results 
shown above suggest a good association with the other BISAP categories. Although current data could not 
support the use of PCT alone as a solo test, these findings might support the suggestion that adding PCT levels 
to the routine admission panel for such patient will be complementary to the already validated available scores 
to improve the prognostication process. Further data is needed in order to integrate the PCT level into the other 
scoring systems and develop modified predictive models with higher accuracy and clinical value.Our data also 
suggested that serum Procalcitonin is significant in predicting severity of AP at an early stage with cut-off 
value of 1.28 (±3.73) ng/ml in mild form of the disease and 4.81 (±6.05) ng/ml for moderate-severe AP (p- 
value<0.001). Regarding BISAP, it was evident that the best cutoff score of BISAP was 2 which is similar to 
the result stated by Kim et al. [], although some other studies have proposed 3 to be the best cutoff score [].We 
aimed to see the relation between the duration of hospitalization with the severity of the disease and found that 
patients with severe disease are likely to spend more time in the hospital with an average of 17.11 (±9.40) days 
(p-value <0.0001). Beside our primary aim of our study, we noticedthat the use of antibiotics in this study 
population was surprisingly very high even in the mild AP group (76.9%). This shows a deficiency in following 
the current guidelines [6], which recommend against the routine use of antibiotics in AP except in the case of 
severe necrotizing AP (we had only 1 such case in this series) or with the evidence of local infected collections.
Our study had several major limitations. We had only 44 patients over the past 5 years since Procalcitonin 
was first introduced to Makassed General Hospital. This was attributed to deficiencies in documentation in our 
medical records, the lack of knowledge about the importance of PCT in patients with AP, and the recurrent 
occasions of shortage of the laboratory kits supplies. This number is small and a larger number is needed to 
provide better results especially in the nigh BISAP score category. We also were not able to compare the PCT 
to other predictive models like the Ranson’s criteria and the Balthazar score due to the lack of documentation 
in this retrospective study. 
5. CONCLUSION
Serum procalcitonin level is a valuable complementary prognostic marker for assessing the severity of 
AP. We suggest to routinely measure and follow-up serial serum PCT levels on patients presenting with AP. 
It directly correlates with the three classes of the revised Atlanta classification and best correlates with BISAP 
scores of 0 to 3. We suggest a mean cut off value of 2 for denoting a worse prognosis.
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